AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

NORTH CHICAGO, Ill., June 2, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026.

PRNewsWire • 6 hours ago

AbbVie Inc. (ABBV) Presents at EU Clinical Trial Regulation: Latest Developments and Upcoming Opportunities Transcript

AbbVie Inc. (ABBV) Presents at EU Clinical Trial Regulation: Latest Developments and Upcoming Opportunities Transcript

Seeking Alpha • May 29, 2026

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

Addition of VENCLYXTO plus acalabrutinib, with or without obinutuzumab, and VENCLYXTO plus ibrutinib supported by data from Phase 3 AMPLIFY trial, Phase 3 GLOW trial and Phase 2 CAPTIVATE trial Fixed-duration VENCLYXTO-based combination regimens provide patients with additional CLL treatment options that may offer the potential for treatment-free intervals NORTH CHICAGO, Ill., May 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has authorized an expanded label for VENCLYXTO® (venetoclax) to include use in combination with acalabrutinib (with or without obinutuzumab) and use in combination with ibrutinib for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL).

PRNewsWire • May 29, 2026

AbbVie (ABBV) Up 3.5% Since Last Earnings Report: Can It Continue?

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • May 29, 2026

AbbVie Wins FDA Nod for Decnupaz for Rare Blood Cancer Indication

ABBV's Decnupaz wins FDA approval for BPDCN, adding its first blood cancer ADC and a new option for an ultra-rare aggressive malignancy.

Zacks Investment Research • May 28, 2026

US FDA approves AbbVie's rare blood cancer drug

The ​U.S. Food ‌and Drug ​Administration ​on Wednesday ⁠approved ​AbbVie's drug ​to treat blastic ​plasmacytoid ​dendritic cell ‌neoplasm, ⁠a very rare ​type ​of ⁠blood cancer.

Reuters • May 27, 2026

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

- DECNUPAZ is the first and only antibody-drug conjugate (ADC) approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) that is initiated in an outpatient setting - DECNUPAZ marks AbbVie's first ADC approved for blood cancer NORTH CHICAGO, Ill., May 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZTM (pivekimab sunirine-pvzy) for the treatment of adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy with limited treatment options.

PRNewsWire • May 27, 2026

How Did AbbVie's Oncology Portfolio Perform in Q1 Despite Headwinds?

ABBV's oncology revenues dip 3% in Q1 as Imbruvica sales slide, though Venclexta, Elahere and Epkinly post solid gains.

Zacks Investment Research • May 27, 2026

Prediction: These 2 Obesity Drug Stocks Could Double in 2026

The weight loss opportunity is a significant one for companies and investors -- and companies involved have seen their shares soar. Analysts predict the market will reach almost $100 billion within a few years.

The Motley Fool • May 26, 2026

Two Paths to Growth: Johnson & Johnson vs AbbVie

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both posted Q1 2026 results that beat revenue expectations and prompted raised full-year guidance.

24/7 Wall Street • May 25, 2026